The Role of Gonadotropin-Releasing Hormone Antagonists in In Vitro Fertilization

ABSTRACT

Gonadotropin-releasing hormone (GnRH)-antagonists can suppress the pituitary hormone secretion completely within a few hours, allowing the avoidance of premature luteinization within controlled ovarian hyperstimulation (COH) for assisted reproductive technologies (ART) by midcycle administration. Two different protocols were described, which were widely used in COH in several phase II and III studies as well as in clinical practice since the GnRH-antagonists Cetrorelix (Cetrotide℗; Serono International S.A., Geneva, Switzerland) and Ganirelix (Orgalutan℗, Antagon℗; Organon, Oss, The Netherlands) are available on the market. Cetrorelix was applied in single- and multiple-dose protocols; Ganirelix was used until now only according to the multiple-dose protocol. Fertilization rates of >60% as well as clinical pregnancy rates of about 30% per transfer sound most promising. Estradiol secretion is not compromised by the GnRH-antagonists using recombinant follicle-stimulating hormone (FSH) for COH. The incidence of a premature leutinizing hormone (LH) surge is far below 2% while the pituitary response remains preserved, allowing the induction of ovulation by GnRH or GnRH-agonists. However, luteal phase support remains mandatory. The incidence of severe ovarian hyperstimulation syndrome (OHSS) seems to be lower under antagonist treatment than in the long agonistic protocol. Treatment time is significantly shortened. Without any doubt GnRH-antagonists have the potential to become the new standard for controlled ovarian hyperstimulation.

KEYWORD

GnRH-antagonists - premature luteinization - OHSS - Cetrorelix - Ganirelix

REFERENCES

• 1 Diedrich K, Diedrich C, Santos E. Suppression of the endogenous luteinizing hormone surge by the gonadotropin-releasing hormone antagonist Cetrorelix during ovarian stimulation.  Hum Reprod . 1994;  9 788-791
• 2 Olivennes F, Fanchin R, Bouchard P. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in-vitro fertilization cycles: a pilot study.  Hum Reprod . 1995;  10 1382-1386
• 3 Felberbaum R, Reissmann T, Küpker W. Hormone profiles under controlled ovarian stimulation with human menopausal gonadotropin (HMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.  J Assist Reprod Genet . 1996;  13 216-222
• 4 The Ganirelix Dose-Finding Study Group. A double-blind, randomized, dose-finding study to assess the efficacy of the gonadotrophin-releasing hormone antagonist ganirelix (Org 37462) to prevent premature luteinizing hormone surges in women undergoing ovarian stimulation with recombinant follicle stimulating hormone (Puregon).  Hum Reprod . 1998;  13 3023-3031
• 5 Albano C, Felberbaum R E, Smitz J. Controlled ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the GnRH-antagonist Cetrorelix (Cetrotide) and the GnRH-agonist Buserelin.  Hum Reprod . 2000;  15 526-531
• 6 Olivennes F, Belaisch-Allart J, Emperaire J C. Prospective, randomised, controlled study of in-vitro fertilization- embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (Cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).  Fertil Steril . 2000;  73 314-320
• 7 Felberbaum R E, Albano C, Ludwig M. Controlled ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH-antagonist Cetrorelix (Cetrotide℗) according to the multiple dose protocol: results of a prospective non controlled phase III study.  Hum Reprod . 2000;  15 1015-1020
• 8 The European Orgalutran℗ Study Group, Borm G, Mannaerts B. Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomised, multicentre trial.  Hum Reprod . 2000;  15 1490-1498
• 9 Hernandez E R. Embryo implantation: the Rubicon for GnRH antagonists.  Hum Reprod . 2000;  15 1211-1216
• 10 Hsueh A J, Jones P B. Extrapituitary actions of gonadotropin-releasing hormone.  Endocr Rev . 1981;  2 437-461
• 11 Felberbaum R E, Ortmann O, Eick F, Sturm R, Diedrich K. GnRH-Antagonist (Cetrorelix) used for COH in vivo does not impair sexual steroid secretion of granulosa lutein cells in vitro.  Fertil Steril . 1998 (suppl 1);  70 (S109)
• 12 Ortmann O, Oltmanns K, Weiss J. Effects of the GnRH antagonist Cetrorelix on steroidogenesis in human granulosa lutein cells.  Hum Reprod. 1998;  13 (abstract 254)
• 13 The North American Ganirelix Study Group, Fluker M, Grifo J, Leader A. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation.  Fertil Steril . 2001;  75 38-45
• 14 The European and Middle East Orgalutran Study Group. Comparable clinical outcome using the GnRH antagonist Ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation.  Hum Reprod . 2001;  16 644-651
• 15 Kol S, Lightman A, Hillensjö T. High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect outcome of subsequent freeze-thaw cycles.  Hum Reprod . 1999;  14 2242-2244
• 16 Hamm W. Broad clinical experience with Cetrotide (Cetrorelix): results of a large multinational phase IIIb study.  Gyn Endocrinol . 2001 (suppl 1);  15 (17)
• 17 Olivennes F, Fanchin R, Bouchard P, Frydman R. Cetrotide single dose regimen: patient selection and stimulation characteristics.  Gyn Endocrinol . 2001 (suppl 1);  15 (15)
• 18 Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist.  Fertil Steril . 1996;  66 151-153
• 19 Itskovitz-Eldor J, Kol S, Mannaerts B. Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation syndrome: preliminary report.  Hum Reprod . 2000;  15 1965-1968
• 20 Olivennes F. Induction of final oocyte maturation by a single dose of GnRH agonist after Ganirelix treatment.  Gyn Endocrinol . 2001 (suppl 1);  15 (12)
• 21 Albano C, Grimbizis G, Smitz J. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix.  Fertil Steril . 1998;  70 357-359
• 22 Ludwig M, Felberbaum R, Albano C. Plasma and follicular fluid concentrations of GnRH antagonist Cetrorelix after multiple application of different doses for the hormonal stimulation in IVF cycles.  Hum Reprod . 1998;  13 167-168
• 23 Ludwig M, Felberbaum R, Albano C. Cetrorelix levels in plasma and follicular fluid.  Gynecol Endocrinol . 1999 (suppl 1);  13 (15)
• 24 Tavaniotou A, Albano C, Smitz J, Devroey P. Comparison of LH concentrations in the early and mid-luteal phase in IVF cycles after treatment with HMG alone or in association with the GnRH antagonist Cetrorelix.  Hum Reprod . 2001;  16 663-672
• 25 Ludwig M, Riethmüller-Wintzen H, Felberbaum R. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist Cetrorelix.  Fertil Steril . 2001;  75 18-22
• 26 Bonduelle M. Neonatal outcome of pregnancies established after treatment with recombinant FSH and Ganirelix for ART.  Gynecol Endocrinol . 2001 (suppl 1);  15 (13)
• 27 Akman M A, Erden H F, Tosun S B. Addition of GnRH antagonist in cycles of poor responders undergoing IVF.  Hum Reprod . 2000;  15 2145-2147